Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler

Equities research analysts at Piper Sandler started coverage on shares of Merus (NASDAQ:MRUS) in a research note issued on Thursday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $84.00 price target on the biotechnology company’s stock. Piper Sandler’s target price suggests a potential upside of 108.64% from the stock’s previous close.

Several other equities analysts also recently issued reports on MRUS. UBS Group assumed coverage on Merus in a research report on Thursday, October 24th. They set a “buy” rating and a $72.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 2nd. The Goldman Sachs Group started coverage on Merus in a report on Thursday, November 21st. They set a “buy” rating and a $73.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective for the company. Finally, Citigroup increased their target price on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. One analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Merus currently has an average rating of “Buy” and a consensus target price of $85.92.

Merus Stock Up 0.4 %

Shares of NASDAQ:MRUS opened at $40.26 on Thursday. The company’s 50-day moving average price is $41.71 and its 200 day moving average price is $47.37. The company has a market cap of $2.76 billion, a PE ratio of -10.19 and a beta of 1.11. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61.

Institutional Investors Weigh In On Merus

Institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN grew its holdings in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 300 shares during the last quarter. Avior Wealth Management LLC acquired a new position in shares of Merus in the 4th quarter valued at $76,000. nVerses Capital LLC increased its stake in Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares in the last quarter. US Bancorp DE acquired a new stake in Merus during the 3rd quarter worth about $103,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 489 shares in the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.